{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121088","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.439672+00:00","generated_at":"2026-05-30T05:25:22.720982+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Beam Therapeutics discusses Q3 results and ASH abstracts on investor call","bullets":["Investor presentation covered Q3 financial results, but no specific figures provided in filing.","Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.","Company reiterated sickle cell disease strategy and provided business update."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121088","json":"https://secwatch.observer/filing/0000950170-24-121088.json","markdown":"https://secwatch.observer/filing/0000950170-24-121088.md","text":"https://secwatch.observer/filing/0000950170-24-121088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/0000950170-24-121088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/beam-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:25:22.720982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}